PARP7 Inhibitors for oncology
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
90
NCT06458712
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Phase: Phase 1
Role: Lead Sponsor
Start: Nov 21, 2024
Completion: Aug 31, 2028
Loading map...